

Welcome

Dear Colleagues,

On behalf of the Scientific Committee, we are pleased to invite you to the Educational Course of the Lymphoma Working Party (LWP) of the EBMT that will be held in Warsaw on 15th - 17th November 2023.

The ongoing progress in the evolving field of lymphoma treatment and diagnostics makes the constant knowledge update necessary for optimal patient management. The growing role of new immunotherapies like CAR-T, bispecific monoclonal antibodies, and antibody-drug conjugates as well as small molecules targeted therapies rise the question of whether stem cell transplantation is still needed, and if so – in which patients and when to perform the procedure. The aim of this educational course is to discuss the role of stem cell transplantation, autologous and allogeneic, in the current approach to patients with different types of lymphoma, like DLBCL, MCL, indolent B-cell lymphoma, HL and T-cell lymphoma. The meeting will feature plenary lectures, pro and con debates and case-study presentations. The participants will have an excellent opportunity to learn the experts' opinions during plenary lectures, participate in the debates on the controversial hot topics in lymphoma and present their own experience as well to see the cases presented by colleagues from other sites or countries.

We are looking forward to welcoming you in Warsaw

Chair of the Lymphoma Working Party: Bertram Glass
Secretary of the Lymphoma Working Group: Anna Ossami Saidy
Chair of the Educational Subcommittee: Anna Sureda
Local organizers: Iwona Hus, Lidia Gil, Wojciech Jurczak

Wednesday, 15 November 2023

15:00 – 18:00 Scientific Business Meeting (only open to Lymphoma Working Party active members)

Thursday, 16 November 2023

09:00 – 10:05 Session 1

Chairs: Iwona Hus (PL) & Bertram Glass (DE)

09:00 – 09:05 Welcome and introduction

09:05 – 09:35 Principles of SCT in lymphoma

Sebastian Giebel (PL)

09:35 – 10:05 Principles of CAR-T in lymphoma

Peter Dreger (DE)

10:05 – 11:35 Session 2: Mantle cell lymphoma

Chair: Norbert Schmitz (DE)

10:05 – 10:30 Changing landscape of MCL first-line treatment: ASCT and targeted therapies

Sascha Dietrich (DE)

10:30 – 10:55 Sequencing of therapies in MCL in the era of novel therapies – where is the place for alloSCT?

Igor Aurer (HR)

10:55 – 11:15 Discussion and Q&A

11:15 – 11:45 Coffee break

11:45 – 13:15 Session 3: Hodgkin Lymphoma

Chairs: Ali Bazarbachi (LB) & Yasmina Serroukh (NL)

11:45 – 12:10 First-line treatment of HL

Paul J. Bröckelmann (DE)

12:10 – 12:35 Auto / allo SCT in refractory/relapsed HL

Norbert Schmitz (DE)

12:35 – 12:45 Case study: Neurological complication after autologous stem cell transplant in a patient with previous immune checkpoint inhibitor treatment

Karla Oliveros (AR)

12:45 – 12:55 Case study: A case of nivolumab in relapsed gray zone lymphoma following allogeneic HSCT: from ICANS to Complete Remission

Igor Age Kos (DE)

12:55 – 13:15 Discussion and Q&A

13:15 – 14:20 Lunch break

14:20 – 16:40 Session 4: Aggressive B-cell lymphoma

Chair: Peter Dreger (DE)

14:20 – 14:45 First-line treatment of aggressive B-cell lymphoma > state-of-the-art

Wojciech Jurczak (PL)

14:45 – 15:10 Debate: The role of ASCT in the second line of aggressive B-cell lymphoma therapy

Yes -> pro ASCT

Marek Trneny (CZ)

No -> pro CART

Bertram Glass (DE)

15:10 – 15:35 Third and subsequent lines strategies of aggressive B-cell lymphoma treatment

Bertram Glass (DE)

15:35 – 16:00 How to use SCT and CAR-T in the treatment of CNS lymphoma

Anna Ossami Saidy (DE)

16:00 – 16:10 Case study: A 28-Year-Old Man with R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Hulya Yilmaz (TR)

16:10 – 16:20 Case study: Successful bispecific antibody therapy followed by allogeneic stem cell transplantation in a patient with refractory THRLBCL

Joseph Kauer (DE)

16:20 – 16:40 Discussion and Q&A

Friday, 17 November 2023

09:00 – 10:20 Session 5: Indolent lymphoma

Chair: Jan Walewski (PL)

09:00 – 09:25 Clinical dilemma: how to choose between many new treatment options for RR FL patients? Which patients will benefit from SCT?

Silvia Montoto (UK)

09:25 – 09:50 New target and cellular therapies (SCT and CAR-T) for patients with MZL

Andreas Viardot (DE)

09:50 – 10:10 Discussion and Q&A

10:10 – 10:40 Coffee break

10:40 – 12:30 Session 6: T-cell lymphoma

Chair: Iwona Hus (PL)

10:40 – 11:05 Standard and emerging therapies for anaplastic large cell lymphoma. The current role of SCT

Norbert Schmitz (DE)

11:05 – 11:30 Treatment of advanced cutaneous T-cell lymphoma – What's new?

Adele de Masson (FR)

11:30 – 11:40 Case study: The Role of Combination of Brentuximab and Nivolumab in a patient with Chemo resistant Mediastinal Lymphoma indistinguishable between Classical Hodgkin Lymphoma and ALK Negative Anaplastic Large Cell Lymphoma prior to Autologous Stem Cell Transplant – A Case Report from a Tertiary Care Centre in Southern India

Sudeep Vaniyath (IN)

11:40 – 11:50 Case study: Primary refractory angioimmunoblastic T-cell lymphoma successfully treated with haploidentical bone marrow transplant

Fernanda Azevedo (BR)

11:50 – 12:10 Discussion and Q&A

12:20 – 12:35 Closing remarks & farewell

* All presentations have 5 minutes included for Q&A after each one

** Case studies are 10 minutes including 3 minutes for Q&A after each one

THANKS TO OUR SPONSORS!

Silver partner:



Miltenyi Biomedicine

Bronze Partners:



Meeting Supporters:

